This immune phenomenon has been recently reported to limit the anti-tumor efficacy of the anti-PD-1/anti-CTLA-4 combined treatment in a low tumor burden setting characterized by tumor infiltration with partially exhausted T lymphocytes. Here, CTLA4 is linked to neoplasm.